Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe

We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 MDR-TB patients (19.4% HCV), 30 were treated concomitantly (23.3% human immunodeficiency virus-positive). Overall,...

Descripción completa

Detalles Bibliográficos
Autores principales: Melikyan, Nara, Huerga, Helena, Atshemyan, Hakob, Kirakosyan, Ohanna, Sargsyants, Narina, Aydinyan, Tsovinar, Saribekyan, Nora, Khachatryan, Naira, Oganezova, Izabella, Falcao, Joana, Balkan, Suna, Hewison, Cathy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896641/
https://www.ncbi.nlm.nih.gov/pubmed/33634203
http://dx.doi.org/10.1093/ofid/ofaa653
Descripción
Sumario:We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 MDR-TB patients (19.4% HCV), 30 were treated concomitantly (23.3% human immunodeficiency virus-positive). Overall, 76.7% achieved HCV treatment success (95.8% among tested). One patient (3.3%) experienced a serious adverse event.

Ejemplares similares